Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the…
| Price | $2.05 |
|---|---|
| Market cap | $86.38M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NASDAQ |
| 52-week range | 1.13-2.89 |
| Beta | 0.28 |
Explore LUNG's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.